Due to the critical role of RASON in KRAS-induced tumorigenesis and maintenance, as well as the aberrant overexpression of RASON in many cancers (our unpublished data), targeting RASON, either alone or in combination with other KRAS pathway inhibitors, may provide a novel approach for treating KRAS mutant cancers. This evidence concerns the gene LINC00511 and cancer.